Cargando…

High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

BACKGROUND: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Romano, Kara D., Hill, Colin, Trifiletti, Daniel M., Peach, M. Sean, Horton, Bethany J., Shah, Neil, Campbell, Dylan, Libby, Bruce, Showalter, Timothy N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048838/
https://www.ncbi.nlm.nih.gov/pubmed/30012164
http://dx.doi.org/10.1186/s13014-018-1074-2
_version_ 1783340172210864128
author Romano, Kara D.
Hill, Colin
Trifiletti, Daniel M.
Peach, M. Sean
Horton, Bethany J.
Shah, Neil
Campbell, Dylan
Libby, Bruce
Showalter, Timothy N.
author_facet Romano, Kara D.
Hill, Colin
Trifiletti, Daniel M.
Peach, M. Sean
Horton, Bethany J.
Shah, Neil
Campbell, Dylan
Libby, Bruce
Showalter, Timothy N.
author_sort Romano, Kara D.
collection PubMed
description BACKGROUND: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. METHODS: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. RESULTS: Fifty-six women with FIGO IB1 – IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D(2cc) was ≥80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D(2cc) ≥ 65 Gy and seven patients had a sigmoid D2cc ≥ 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. CONCLUSIONS: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of: less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
format Online
Article
Text
id pubmed-6048838
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60488382018-07-19 High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events Romano, Kara D. Hill, Colin Trifiletti, Daniel M. Peach, M. Sean Horton, Bethany J. Shah, Neil Campbell, Dylan Libby, Bruce Showalter, Timothy N. Radiat Oncol Research BACKGROUND: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. METHODS: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. RESULTS: Fifty-six women with FIGO IB1 – IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D(2cc) was ≥80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D(2cc) ≥ 65 Gy and seven patients had a sigmoid D2cc ≥ 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. CONCLUSIONS: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of: less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid. BioMed Central 2018-07-16 /pmc/articles/PMC6048838/ /pubmed/30012164 http://dx.doi.org/10.1186/s13014-018-1074-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Romano, Kara D.
Hill, Colin
Trifiletti, Daniel M.
Peach, M. Sean
Horton, Bethany J.
Shah, Neil
Campbell, Dylan
Libby, Bruce
Showalter, Timothy N.
High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
title High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
title_full High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
title_fullStr High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
title_full_unstemmed High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
title_short High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
title_sort high dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048838/
https://www.ncbi.nlm.nih.gov/pubmed/30012164
http://dx.doi.org/10.1186/s13014-018-1074-2
work_keys_str_mv AT romanokarad highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT hillcolin highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT trifilettidanielm highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT peachmsean highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT hortonbethanyj highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT shahneil highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT campbelldylan highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT libbybruce highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents
AT showaltertimothyn highdoseratetandemandovoidbrachytherapyincervicalcancerdosimetricpredictorsofadverseevents